Wall Street Boosts Compass Pathways as COMP360 Durability Data Strengthens Path to 2027 Approval

Positive six-month COMP360 results trigger analyst upgrades and higher price targets for Compass Pathways. Strong durability data clears path to potential 2027 FDA approval in treatment-resistant depression.